FILTER BY PRODUCT
FILTER BY THERAPY AREA
Afshin Dowlati, et al. Abstract CT155: Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer
Elena Garralda, et al. Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
Xiaohua Wu, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Jian Li, et al. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
Liu ZL, et al. Dose Modification for Chinese Patients on Niraparib Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer: A Post Hoc Analysis. Presented as a poster presentation at the ESGO 2021 Congress, held virtually and in Prague, Czech Republic, October 23-25, 2021
Ai XH, et al. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. J Thorac Oncol. 2021 Aug; 16(8):1403-1414.
Howard JF, et al., Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-536.
Wang J, et al. Safety Assessment of Niraparib Individualized Starting Dose in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized, Double-Blind, Placebo-Controlled, Phase III NORA Trial. Presented as a poster presentation at the ASCO Virtual 2021 Congress, held virtually, June 4-8, 2021
Wu LY, et al. Efficacy of Niraparib Maintenance Therapy in Chinese Women with Platinum-Sensitive Recurrent Ovarian Cancer with and Without Secondary Cytoreductive Surgery: Results from the NORA Trial. Presented as a poster presentation at the ASCO Virtual 2021 Congress, held virtually, June 4-8, 2021
Mok T, et al., KRYSTAL-12: A Randomized Phase 3 Study of Adagrasib (MRTX849) vs Docetaxel in Patients With Previously Treated Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation, poster presentation at 2021 ASCO Annual Meeting.
Piotrowska Z, et al., Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). Presentation at ASCO 2021 Virtual Congress
Wang B, et al. ZL-1201, A Differentiated CD47 Therapeutic Antibody with a Potentially Improved Hematological Safety Profile. Presented as a poster presentation at the AACR Virtual 2021 Congress, held virtually, April 10-15, 2021
Li J, et al. Population and Non-Compartmental Pharmacokinetic Analysis of Ripretinib and its Active Metabolite in Chinese Patients with Gastrointestinal Stromal Tumor. Presented as a poster presentation at the AACR Virtual 2021 Congress, held virtually, April 10-15, 2021
Wu XH, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021 Apr; 32(4):512-521
Rugo HS, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932.
Yang JX, et al. Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Huang QD, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or ≥12 months: a subgroup analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Yin RT, et al. Evaluation of treatment response to niraparib in patients with platinum-sensitive recurrent ovarian cancer and measurable lesions at baseline: a sub-analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Wainberg ZA, et al., A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT), Journal of Clinical Oncology 2021; 39:3_suppl: 160-160.
Cho BC, et al., Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors. Presentation at 2020 World Conference on Lung Cancer virtual congress.
Wang J, et al., A Phase 1, Open-Label Study of MGD013 (Tebotelimab), a Bispecific DART® Molecule Binding PD-1 and LAG-3, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, presentation at 2020 ASH Annual Meeting
Bannerji R, et al., Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy, presentation at 2020 ASH Annual Meeting
Zhu JQ. Efficacy and Safety of Niraparib in Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose. Efficacy and Safety of Niraparib in Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose. Presented as an oral presentation at the ESMO Asia Virtual 2020 Congress, held virtually, November 20-22, 2020
Ai XH. A Randomized Double-blind Phase III Study of Niraparib versus Placebo as Maintenance Therapy in Extensive-stage Small Cell Lung Cancer. Presented as an oral presentation at the ESMO Asia Virtual 2020 Congress, held virtually, November 20-22, 2020
Patel, MR, et al., A Phase 1 Evaluation of Tebotelimab, a Bispecific PD-1 x LAG-3 DART® Molecule, in Combination with Margetuximab in Patients with Advanced HER2+ Neoplasms, poster presentation at 2020 SITC Annual Meeting
Hong DS. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1). Presented at: 32nd EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. October 24-25, 2020.
Zhu YS, et al. 尼拉帕利在肿瘤患者中的群体药代动力学分析. Presented as a poster at the CSCO 2020 Virtual congress, held virtually, China, September 19-26, 2020
抗PD-1/LAG-3 双亲和重定位 (DART®) 分子 Tebotelimab (MGD013) 单药治疗或与VEGFR/FGFR抑制剂布立尼布联合治疗在中国晚期肝癌 (HCC) 患者中的I期、开放性、剂量递增研究. Presentated as a oral presentation at the CSCO 2020 Congress, held virtually, China, September 19-26, 2020
Wu XH, et al. Individualized Starting Dose of Niraparib in Patients with Platinum Sensitive Recurrent Ovarian Cancer (NORA): A Randomized, Double Blind, Placebo Controlled, Phase III Trial. Presented as an oral presentation at the ESMO Virtual 2020 Congress, held virtually, September 19-21, 2020
Rao S, et al., POD1UM -202: Phase 2 Study of Retifanlimab in Patients With Squamous Carcinoma of the Anal Canal Who Progressed Following Platinum -Based Chemotherapy, presentation at ESMO 2020 Virtual Congress
Blay, J-V et al., Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumours (Invictus): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial, Lancet Oncol 2020; Volume 21, Issue 7: 932-934.
Luke fJ, et al., A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms, presentation at 2020 ASCO Virtual Scientific Program
Sagan O, et al., Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis, Antimicrobial Agents and Chemotherapy 2020; 64(3): 01506-19.
Gonzalez-Martin A, et al., Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer, N Engl J Med 2019; 381:2391-2402, DOI: 10.1056/NEJMoa1910962.
Giovanni L Ceresoli, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019 Dec;20(12):1702-1709.
O’Riordan W, et al., Once-daily Oral Omadacycline Versus Twice-Daily Oral Linezolid for Acute Bacterial Skin and Skin Structure Infections (OASIS-2): a Phase 3, Double-Blind, Multicentre, Randomised, Controlled, Non-Inferiority Trial, Lancet Infect Dis 201; 19: 1080–90. Published online August 29, 2019
Wu XH, et al. A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data from the NORA Study. Presented as a poster presentation at the ESMO 2019 Congress, held in Barcelona, Spain, September 27-October 1, 2019
Moore KN, et al., Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol 2019; 20: 636-48.
Zhang J, et al. A Phase I Study to Evaluate the Pharmacokinetics (PK) and Safety of Niraparib in Chinese Patients with Epithelial Ovarian Cancer (OC). Presented as a poster presentation at the AACR 2019, held in Atlanta, USA, March 29-April 3, 2019
Fredrick M Abrahamian, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med. 2019 Feb;380(6):528-538.
Stets R, et al., Omadacycline for Community-Acquired Bacterial Pneumonia, N Engl J Med 2019; 380:517-527, DOI: 10.1056/NEJMoa1800201
O’Riordan W, et al., Omadacycline for Acute Bacterial Skin and Skin-Structure Infections, N Engl J Med 2019; 380:528-538, DOI: 10.1056/NEJMoa1800170
Stupp R, et al., Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial, JAMA 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
Mirza MR, et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016; 375:2154-2164, DOI: 10.1056/NEJMoa1611310.
Stupp R, et al., NovoTTF-100: A versus physician’s choice chemotherapy in recurrent glioblastoma: A Randomised Phase III Trial of a Novel Treatment Modality, European Journal of Cancer 2012; 48: 2192-2202.